Japan CAR-T Market Report: Autologous vs Allogeneic Therapies and Key Drug Trends | Top Companies are Gilead Sciences, Inc., Bristol Myers Squibb Company, Johnson & Johnson Services, Inc

The Japan CAR-T cell therapies market reached US$ 346.00 million in 2024 and is expected to reach US$ 1,350.15 million by 2033, growing at a CAGR of 16.3% during the forecast period 2025-2033.

According to DataM Intelligence has published a new research report on "Japan CAR-T Cell Therapies Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

📌 Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/japan-car-t-cell-therapies-market?rk

➣ Recent Developments:

✅ In 2025, Japan established its first next-generation commercial-scale CAR‐T manufacturing facility in Kashiwa, featuring automated production to reduce costs and turnaround time.

✅ Abecma (idecabtagene vicleucel), a BCMA-directed CAR‐T therapy for multiple myeloma, received expanded approval for use earlier in the treatment process, giving patients access after fewer prior therapies.

✅ Yescarta (axicabtagene ciloleucel), a CD19-directed CAR‐T therapy, continues to be a key option for relapsed or refractory large B-cell lymphomas in Japan.

✅ Researchers at Kyushu University developed a spinal fluid biomarker test to help predict neurotoxicity (ICANS) risk prior to CAR‐T therapy, improving patient safety and treatment planning.

➣ Latest Mergers & Acquisitions:

✅ Gilead / Kite Pharma acquired Interius BioTherapeutics for US$350 million - adding an in‐vivo CAR‐T delivery platform to simplify therapy administration.

✅ Bristol Myers Squibb (BMS) acquired 2seventy bio for US$286 million - consolidating full ownership of Abecma's CAR‐T program, streamlining development and revenue.

✅ Roche completed acquisition of Poseida Therapeutics for US$1.5 billion - expanding allogeneic/off-the-shelf CAR‐T capabilities and strengthening hematologic and solid tumor pipelines.

✅ AstraZeneca acquired EsoBiotec for up to US$1 billion - targeting in‐vivo cell‐therapy platforms to accelerate next-generation CAR‐T therapies.

➣ Top Industry Players:

Gilead Sciences, Inc., Bristol Myers Squibb Company, Johnson & Johnson Services, Inc., and Novartis AG, among others.

📌 Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=japan-car-t-cell-therapies-market?rk

➣ Key Segments:

By Therapy Type: Autologous CAR-T Cell Therapy | Allogeneic CAR-T Cell Therapy

By Drug Type: Abecma | Breyanzi | Carvykti | Tecartus | Kymriah | Yescarta

By Target Antigen: CD19 | BCMA (B-cell Maturation Antigen) | CD20 | CD22 | CD30 | Others

By Application: Acute Lymphoblastic Leukemia (ALL) | Non-Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | Multiple Myeloma (MM) | Follicular Lymphoma | Others

📌 Get Customization in the report as per your requirements: https://datamintelligence.com/customize/japan-car-t-cell-therapies-market?rk

📌 Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/japan-car-t-cell-therapies-market?rk

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

☛ Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?rk

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.